Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
Holding XOMA?
Track your performance easily
XOMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.50 - $35.00
Previous CloseN/A
Volume8.24K
Average Volume (3M)54.09K
Market Cap
$314.60M
Enterprise Value$286.21M
Total Cash (Recent Filing)$25.74M
Total Debt (Recent Filing)$25.31M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Mar 06, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding11,782,723
10 Day Avg. Volume97,746
30 Day Avg. Volume54,093
Standard Deviation0.16
R-Squared0.09
Alpha0.00136
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.56
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue17.70
Enterprise Value/Gross Profit60.15
Enterprise Value/Ebitda-12.76
Forecast
1Y Price Target
$123.00Price Target Upside364.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Xoma News
PremiumCompany Announcements
XOMA Royalty’s Third Quarter 2024 Financial Insights
PremiumPre-Earnings
Xoma Corp. (XOMA) Q3 Earnings Cheat Sheet
Bulls Say, Bears Say
Bulls Say
Product GrowthVabysmo is winning market share and could continue to exceed consensus expectations.
Regulatory ApprovalFDA approved Zevra's arimoclomol as the first treatment for Niemann-Pick Disease Type C.
Strategic AcquisitionXoma's acquisition of Pulmokine to obtain a royalty interest in seralutinib has the potential to create meaningful shareholder value.
Bears Say
Clinical TrialsThere is risk to seralutinib's Phase III success despite the ongoing trial's design adjustments.
EarningsXOMA announced 3Q24 results, posting EPS of ($1.59) vs. an estimate of ($0.50); the discrepancy came from a one-time non-cash charge of $14 million from the return of assets from the Agenus deal in 2015.
Financial Performance3Q24 GAAP EPS of -$1.59 was below the consensus of -$0.44, due to a $14M non-cash impairment charge related to the 2017 Agenus royalty acquisition.
---
Ownership Overview
1.53% Insiders
13.00% Mutual Funds
40.44% Other Institutional Investors
39.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $19.50 and its highest was $35.00 in the past 12 months.
What is Xoma Corp’s market cap?
Xoma Corp’s market cap is $314.60M.
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is Mar 06, 2025 which is in 34 days.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on Nov 07, 2024. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of -$0.437 by -$1.153.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -0.3.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 11,782,723 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of -$1.59 in its last earnings report, missing expectations of -$0.437. Following the earnings report the stock price went down -6.962%.
Which hedge fund is a major shareholder of Xoma Corp?
Currently, no hedge funds are holding shares in XOMA
---
Xoma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$123.00 (364.15% Upside)
$123.00 (364.15% Upside)
Hedge Fund Trend
Increased
By 23.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.56%
12-Months-Change
Fundamentals
Return on Equity
-35.33%
Trailing 12-Months
Asset Growth
79.98%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
---
XOMA Stock 12 Month Forecast
Average Price Target
$123.00
▲(364.15% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Corcept Therapeutics
―
Madrigal Pharmaceuticals
―
GlycoMimetics
―
AnaptysBio
―
Best Analysts Covering XOMA
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+19.56%
reiterated a buy rating 24 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +19.56% per trade.
---